Comparative Haematological Safety Profiles of AT+SP AND AQ+SP for the Treatment of Uncomplicated PlasmodiumFalciparum Malaria in Children
Keywords:
Haem-safety-profiles, malaria.Abstract
Haematological profiles serve as strong indicators of recovery and the safety of antimalarial drugs in children. The present study evaluated the safety of Artesunate + Sulphadoxine-Pyrimethamine (AT+SP) and Amodiaquine + Sulphadoxine-Pyrimethamine (AQ+SP) combination therapies in the treatment on thirteen different haematological and a biochemical parameters. The study was carried out in malaria holo-endemic settlements in northern Nigeria, among 313 children with uncomplicated Plasmodium falciparum malaria randomly selected, between July and September, 2012 using therapeutic efficacy protocols on antimalarial drugs. There were no cases of lympopenia, and recoveries were faster in AT+SP than AQ+SP for leucocytosis (37.5% vs 17.39%), anaemia (82.23% vs 78.03%), thrombocytopenia (90.13% vs 88.20%), monocytosis (30.92% vs 28.01%) and eosinophilia (31.68%) than AQ+SP (18.01%) in 28 days. Conversely, the recoveries from AQ+SP were higher than AT+SP for neutrophilia (32.89% vs 38.45%), and ALT (76.31% vs 78.33%) over 28 days. In contrast, there were slight adverse effects in both drugs on leucopenia, thrombocytosis, neutropenia, lympocytosis and monocytopenia in the range of 1.97 - 20.50% for AT+SP compared to 3.29 - 11.18% for AQ+SP. Except for monocytopenia, the adverse effects due to AT+SP was higher compared to AQ+SP.
References
P. H. Abro, M. U. Abdalla, J. Y. Nadeem, A. S. Ahmed, A. Dujana, and A. S. Ahmed,
A. C. Anand, and P. Puri,
M. I. Award, A. M. Y. Alkadru, R. H. Behrens, O.Z. Barak, and I. B. Eltayeb,
D. J. Bell, S. K. Nyirongo, M. Mukaka, E. E. Zijlstra, C.V. Plowe. M.E. Molyneoux, S.A. Ward, and P.A.Winstanley,
R. Biswas, G. Sengupta, and M.A.Mundle,
M. Cheesbrough,
L.H. Camacho, W.G. Wilairatana, W. G. Mercader, M. A. Brittenham, G. M. Looareesuwan, S. and Gordeuk, V. R.,
L. M. Erhart, K. Yingyuen, N. Chuanak, N. Buathong, A. Laoboonchai, R. S. Miller, S. R. Meshwick, R. A. Gasser, and C. Wongsrichanalai,
E. G. Giannini, T. Testa, and V. Savarino,
H. Gilles,
K. C. Kain,
K. Taha, Z. Soheir, I. Majid, M. Gamal, B. Ghassan,
A. Kwadwo, O. S. Koram, U. Greg, B. N. Fred, J. K. Baired, L. H. Stephen, and K. N. Frances,
J. A. V. Kurzhals, B. Q. Adabayeri, B. D. Goka, J.O. Akanmori, F. K.Oliver-Commey, C. Nkrumah, and L. H. Behr,
T. B. Lathia, and R, Joshi,
Q. Llorenc
A. R. Memoni and S, Afsar,
National Malaria Control Programme,
P. E. Olumese, O. K. Amodu, A. Bjorkman, A. A. Adeyemo, R. A. Gbadegesin, and O. Walker,
C. O. Obonyo, J. Vulule, W. S. Akhwale, and D. E. Grobbee,
R. E. L. Paul, and P. Brey,
L. H. Perrin, L.J. Mackey, and P. A, Miescher,
R. E. Phillips, S. Looareesuwan, D.A. Warrell, S.H. Lee, J. Karbwang, M.J. Warrell, N. J. White, C. Swasdichai, and D.J.Weatherall,
S. L. Pitmang, T. D. Thacher, J. K. A. Madaki, D. Z. Egah, and P. R. Fischer,
S. Rojanasthien, V. Surakamolleart, S. Boonpucknavig and P. Isarangkura,
P. J. Rosenthal,
J .W. Sear,
A. P. Schapira, F. Beales, and M. E. Halloran,
T. W. Scott, W. Takken, B. G. J. Knols, and C. Boete,
D. F. Verhage, D. S. C. Telgt, J. T. Bousema, C. C. Hersen, G.J.A. Van Gemert, J. W. M. Vander-Meer,and R.W.Sauerwein,
C. J. Woodrow, R. K. Haynes and S.Krishna S.,
World Health Organization,
World Health Organization,
World Health Organization, Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation. WHO/CDS/RBM/2001.35, WHO, Geneva, 2001.
World Health Organization,
World Health Organization,
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.
